Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive pharmacological prophylaxis for venous thromboembolism (VTE), unless there are specific contraindications. However, the optimal preventive strategy in terms of intensity of anticoagulation for these patients is not well established. Objectives. To investigate the impact of individualized regimens of enoxaparin on the development of VTE and on the risk of major bleeding complications during hospitalization in patients with COVID-19 infection. Methods. All consecutive patients admitted to the medical wards of six Italian hospitals between 15 September and 15 October 2020 with COVID-19 infection of moderate severity were administered enoxaparin i...
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patie...
The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COV...
Background: COVID-19 is associated with inflammation and an increased risk of thromboembolic complic...
Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive p...
Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive p...
Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive p...
A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with Corona...
Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome-cor...
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmona...
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmona...
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but incr...
Coronavirus disease 2019 (COVID-19) carries a high risk of vascular thrombosis. However, whether a s...
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but incr...
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but incr...
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patie...
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patie...
The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COV...
Background: COVID-19 is associated with inflammation and an increased risk of thromboembolic complic...
Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive p...
Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive p...
Background. According to recent guidelines, all hospitalized patients with COVID-19 should receive p...
A pro-thrombotic milieu and a higher risk of thrombotic events were observed in patients with Corona...
Background: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome-cor...
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmona...
COVID-19 infection causes respiratory pathology with severe interstitial pneumonia and extra-pulmona...
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but incr...
Coronavirus disease 2019 (COVID-19) carries a high risk of vascular thrombosis. However, whether a s...
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but incr...
Background: Therapeutic/intermediate-dose heparin reduces the risk of thromboembolic events but incr...
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patie...
Importance: The use of anticoagulant therapy with heparins decreased mortality in hospitalized patie...
The use of heparin has been shown to decrease the mortality in hospitalized patients with severe COV...
Background: COVID-19 is associated with inflammation and an increased risk of thromboembolic complic...